Sarcoidosis Drug Market Report 2026

Sarcoidosis Drug Market Overview

• Sarcoidosis Drug market size has reached to $7.88 billion in 2025 • Expected to grow to $10.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Rising Clinical Trials Driving Growth In The Market Due To Increasing Demand For Personalized And Innovative Treatments • Market Trend: Innovation In Sarcoidosis Treatment With Advancements In Anti-Tnfα Biologics And Orphan Drug Developments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sarcoidosis Drug Market?

A sarcoidosis drug is any pharmacologic agent used to control the abnormal immune response and granuloma formation characteristic of sarcoidosis, a multisystem inflammatory disorder most often affecting the lungs and lymph nodes. These drugs help reduce symptoms and prevent organ damage. The main types of sarcoidosis drugs are for ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, sarcoidosis of the spleen and bone marrow, and pulmonary sarcoidosis. Ocular sarcoidosis specifically refers to eye inflammation caused by sarcoidosis, marked by granuloma formation in eye tissues. This condition can result in symptoms such as redness, pain, and even vision loss. Treatment options include corticosteroids, immunosuppressants, antimalarials, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are indicated for conditions involving the lungs, skin, heart, and nervous system. The drugs may be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare facilities.

What Is The Sarcoidosis Drug Market Growth Forecast?

The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to personalized medicine adoption, growth in companion diagnostics, ai-enabled genomics, rising demand from pharma companies, government genomics initiatives. Major trends in the forecast period include expansion of precision medicine applications, rising use of cfdna and liquid biopsy, high-throughput genotyping technologies, integration with ai-based data analysis, growth in pharmacogenomics.

Global Sarcoidosis Drug Market Segmentation

1) By Type: Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen and Bone Marrow, Pulmonary Sarcoidosis 2) By Mechanism of Action: Corticosteroid, Immunosuppressants, Antimalarial, Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors 3) By Indication: Lung Involvement, Skin Involvement, Cardiac Involvement, Neurological Involvement 4) By Route of Administration: Oral, Intravenous, Topical 5) By End User: Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Users Subsegments: 1) By Ocular Sarcoidosis: Anterior uveitis, Posterior uveitis, Panuveitis, Conjunctival sarcoidosis 2) By Neurosarcoidosis: Cranial neuropathy, Meningeal involvement, Spinal cord sarcoidosis, Peripheral neuropathy 3) By Cardiac Sarcoidosis: Arrhythmias, Heart block, Cardiomyopathy, Heart failure 4) By Musculoskeletal Sarcoidosis: Arthropathy, Myopathy, Bone lesions, Sarcoid arthritis 5) By Cutaneous Sarcoidosis: Lupus pernio, Erythema nodosum, Maculopapular lesions, Scar sarcoidosis 6) By Renal Sarcoidosis: Granulomatous interstitial nephritis, Nephrocalcinosis, Hypercalciuria, Tubulointerstitial nephritis 7) By Hepatic Sarcoidosis: Granulomatous hepatitis, Hepatomegaly, Cholestasis, Portal hypertension 8) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly, Hypersplenism, Bone marrow infiltration, Pancytopenia 9) By Pulmonary Sarcoidosis: Hilar lymphadenopathy, Interstitial lung disease, Fibrotic sarcoidosis, Bronchial obstruction

What Is The Driver Of The Sarcoidosis Drug Market?

The increasing number of clinical trials is expected to propel the growth of the sarcoidosis drug market going forward. Clinical trials are research studies conducted on humans to evaluate the safety, effectiveness, and side effects of medical treatments or interventions. Clinical trials are increasing due to the growing demand for personalized and innovative treatments requiring rigorous safety and efficacy testing. Sarcoidosis drugs are used in clinical trials to evaluate their efficacy, safety, and impact on disease progression, aiming to improve patient outcomes and identify more effective treatments. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade body, the total number of industry-sponsored clinical trials initiated in the United Kingdom increased from 411 in 2022 to 426 in 2023, while Phase III trial initiations grew by 16.5 percent over the same period, rising from 182 to 212. Therefore, the increasing number of clinical trials is driving the growth of the sarcoidosis drug industry.

Key Players In The Global Sarcoidosis Drug Market

Major companies operating in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

Global Sarcoidosis Drug Market Trends and Insights

Major companies are operating in the sarcoidosis drug market, focusing on developing innovative solutions such as anti-TNFα monoclonal antibodies to address treatment-resistant cases and improve disease management outcomes. Anti-TNFα monoclonal antibodies are biologic drugs that block tumor necrosis factor-alpha (TNFα) to reduce inflammation and tissue damage in conditions such as sarcoidosis and other autoimmune diseases. For instance, in November 2023, Xentria Inc., a US-based pharmaceutical company, received an orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16 to treat sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets and blocks tumor necrosis factor alpha (TNFα), a key inflammatory molecule implicated in the formation of granulomas characteristic of sarcoidosis. It aims to disrupt the inflammatory pathway and potentially slow the progression of granuloma formation in patients with sarcoidosis, particularly pulmonary sarcoidosis, which affects the lungs.

What Are Latest Mergers And Acquisitions In The Sarcoidosis Drug Market?

In June 2023, Xentria Inc., a US-based pharmaceutical company, collaborated with Meitheal Pharmaceuticals Inc. With this collaboration, Xentria aim to accelerate the development and commercialization of XTMAB-16 to provide an effective, targeted treatment for pulmonary sarcoidosis, addressing a critical unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based pharmaceutical company that manufactures sarcoidosis drugs.

Regional Insights

North America was the largest region in the sarcoidosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sarcoidosis Drug Market?

The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sarcoidosis Drug Market Report 2026?

The sarcoidosis drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.